Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01011)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the Shareholders and potential investors that, based on the information currently available to the Group, the Group is expected to record a loss for the six months ended 30 June 2020 (the "**Period Under Review**"). As compared with the corresponding period in 2019, the Group may turn profit into loss.

This announcement is made by China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the information currently available to the Group, the board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders (the "**Shareholders**") and potential investors of the Company that the Group is expected to record a loss for the Period Under Review and as compared with the corresponding period in 2019, a turnaround from profit to loss may be recorded. This is mainly because the Group's sales revenue was hindered by the decline in the number of outpatient visits and hospitalized patients as a result of various national control measures during the Period Under Review in the face of coronavirus pandemic. Despite this, the sales of the Group's main product, Shusi, is stable.

The announcement is made solely based on the preliminary assessment of the Board after reviewing the estimated financial results of the Group and the information currently available to the Group, which is still in the process of being finalised and which has not been reviewed by the Company's auditors. Further details of the Company's financial performance will be provided in the announcement for the interim results of the Group for the Period Under Review, which is expected to be published before the end of August 2020.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 31 July 2020

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Tze Shan Hailson Yu, Mr. Pan Fei and Dr. Zhao Yubiao.